A1 Refereed original research article in a scientific journal
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wildtype p53 to Exert the Dominant-Negative Effect
Authors: Klemm, Nancy; Schimmer, Roman R.; Konrad, Nils K.; Thelen, Flavian; Fullin, Jonas; Topçu, Ebru; Koch, Christian; Treacy, Milena; Leventhal, Matthew Joseph; Bühler, Marco M.; Lysenko, Veronika; Theocharides, Alexandre P. A.; Kurppa, Kari J.; Balabanov, Stefan; Baubec, Tuncay; Krivtsov, Andrei V.; Miller, Peter G.; Armstrong, Scott A.; Ebert, Benjamin L.; Manz, Markus G.; Nombela-Arrieta, Cesar; Boettcher, Steffen
Publisher: Waverly Press
Publication year: 2025
Journal: Cancer Research
Journal name in source: Cancer Research
Volume: 85
Issue: 11
First page : 1978
Last page: 1996
ISSN: 0008-5472
eISSN: 1538-7445
DOI: https://doi.org/10.1158/0008-5472.CAN-24-1136
Web address : https://doi.org/10.1158/0008-5472.can-24-1136
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/491934423
Missense mutants of p53 - such as the frequent hotspot variant R248Q - exert a dominant-negative effect (DNE) on wildtype (WT) p53 in cancer cells with monoallelic TP53 mutations. However, the precise functional and molecular mechanisms of the DNE have remained elusive due to a lack of appropriate model systems. Here, we developed a variety of model systems, including CRISPR-edited human isogenic cell lines and transcriptional reporter cell lines, and targeted protein degradation assays that were combined with functional and molecular analyses to functionally characterize the DNE. Formation of heterotetramers between R248Q and WT p53 impaired proper WT p53 functionality by preventing DNA binding and subsequent target gene transactivation. Furthermore, the markedly increased protein half-life of R248Q led to supraphysiologic levels of R248Q, which was critically required for the DNE. Drug-induced targeted protein degradation of R248Q to lower the R248Q:WT ratio restored the transcriptional activity of WT p53, induced anti-proliferative effects in cancer cells in vitro, and elicited strong therapeutic activity in vivo. Together, this study provides mechanistic insights into the DNE of p53 missense mutants and indicates that the DNE represents a promising therapeutic target.
Downloadable publication This is an electronic reprint of the original article. |  |
Funding information in the publication:
This work was supported by research grants of the EHA Kick-off Grant (KOG-202209-02593) to F.T., the KRAK Physician Scientist Fellowship and the Jacques and Gloria Gossweiler Foundation to R.R.S., National Institutes of Health (NIH) (K08-CA263181 to P.G.M., Swiss National Science Foundation (310030_184747/1) to M.G.M., the Swiss National Science Foundation (310030_219699) to C.N.A. as well as research grants by the Swiss Cancer League (KFS-4885-08-2019), the Helmut Horten Foundation, the Promedica Foundation, and the Swiss National Science Foundation (310030_197562/1) to S.B.
